leisure time -WSS

leisure time

author：fashion 2025-09-30 00:47:22 - browse：543

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Pfizer, Moderna say biotech, pharma drug development is a sprint

hotspot

WSS

Biotech investment managers search for lucrative opportunities

STAT Virtual Event: The State of Biosimilars: What to Watch

Startup Neumora takes a novel depression drug to Phase 3

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Pfizer, Moderna say biotech, pharma drug development is a sprint

Startup Neumora takes a novel depression drug to Phase 3

leisure time

leisure time

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Key House panel plots a new health care package

Malaria cases in Florida and Texas: Here’s what you need to know

Asbestos ban is immediate, but health effects will linger for decades

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Adam's Take: Intra

At least 13 dead in Texas as scorching temps continue

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Wikipedia

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Listen: Wegovy in the brain & pivotal Alzheimer's data

Doctors find melanoma drugs effective against rare brain cancer

Texas board proposes rules on abortion law emergency exemption

Readout Newsletter: Illumina, CRISPR, Regeneron

Why hospitals are withdrawing from US News rankings

focus

hotspot

hotspot

leisure time